维康药业(300878) - 2024 Q4 - 年度业绩预告

Financial Performance - The company expects a net loss of RMB 110 million to RMB 150 million for the year 2024, a decrease of 1268% to 1766% compared to the previous year's loss of RMB 8.04 million [3]. - The expected net loss after deducting non-recurring gains is RMB 190 million to RMB 240 million, a decline of 653% to 852% from last year's loss of RMB 25.22 million [3]. Non-Recurring Gains - The company sold its wholly-owned subsidiaries engaged in pharmaceutical retail, generating an investment income of approximately RMB 90 million, which is classified as non-recurring gains [5]. Impairment and Depreciation - Fixed asset impairment provisions amounting to RMB 87.42 million were recorded due to underutilization of production capacity [5]. - The depreciation of fixed assets increased significantly due to the transfer of fixed assets from the first and second phases of the pharmaceutical health industry park, further affecting profits [6]. Sales and Revenue Challenges - The decline in product prices and subpar sales and management performance led to a decrease in both sales revenue and gross margin [6]. - The introduction of drug traceability codes and changes to product instructions resulted in increased product returns, negatively impacting revenue and profit, especially in Q4 2024 [6]. Regulatory Investigation - The company is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [7].